SCHEMBL24828940

SCHEMBL24828940

CC1(C)O[C@@H]2[C@H](O1)[C@@H](CO)O[C@H]2n1ccc(NOC(=O)[C@@H](N)c2ccccc2)nc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
P2RY6 Q15077 4/20 0.38
P2RY2 P41231 2/20 0.38
P2RY4 P51582 2/20 0.38
LMNA P02545 2/20 0.38
THRB P10828 1/20 0.38
MTOR P42345 1/20 0.38
MDM2 Q00987 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
PI4KA P42356 1/20 0.38
PI4K2B Q8TCG2 1/20 0.38
PI4K2A Q9BTU6 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
NT5E P21589 1/20 0.38
P2RY14 Q15391 1/20 0.38
ALDH1A1 P00352 2/20 0.37
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24829351 0.89 P2RY6 (0.43) P2RY6P2RY2P2RY4LMNATHRB
SCHEMBL24828993 0.89 P2RY6 (0.43) P2RY6P2RY2P2RY4LMNATHRB
SCHEMBL24829178 0.88 P2RY6 (0.40) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829176 0.88 LMNA (0.41) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829177 0.88 LMNA (0.41) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829337 0.88 P2RY6 (0.40) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829350 0.87 LMNA (0.40) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829334 0.87 LMNA (0.40) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829033 0.87 P2RY6 (0.42) POLBP2RY6P2RY2P2RY4LMNA
SCHEMBL24829036 0.86 POLB (0.48) POLBP2RY6P2RY2P2RY4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190782-A1 NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-06-22 US disclosed
US-11541071-B1 Nucleoside derivatives and methods of use thereof Ascletis BioScience Co., Ltd (CN) 2023-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190782-A1 NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF TYMP, NUDT1, PNP POLB 63/4885P2RY6 731/4885P2RY2 1449/4885
US-11541071-B1 Nucleoside derivatives and methods of use thereof TYMP, NUDT1, PNP POLB 63/4885P2RY6 731/4885P2RY2 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.